Literature DB >> 22759598

Tadalafil enhances the inhibitory effects of tamsulosin on neurogenic contractions of human prostate and bladder neck.

Javier Angulo1, Pedro Cuevas, Argentina Fernández, José M La Fuente, Antonio Allona, Ignacio Moncada, Iñigo Sáenz de Tejada.   

Abstract

INTRODUCTION: Lower urinary tract symptoms secondary to benign prostatic hyperplasia (BPH-LUTSs) may be associated with erectile dysfunction (ED). Phosphodiesterase type 5 (PDE5) inhibitors used for treating ED have shown clinical benefit in patients with LUTS but their actions in human LUT tissues are not well defined. AIM: To determine the effects of the long-acting PDE5 inhibitor, tadalafil, on smooth muscle tone in human prostate and bladder neck as well as to evaluate the influence of tadalafil on the efficacy of the α-adrenergic receptor antagonist, tamsulosin, in inhibiting contractile responses in these tissues.
METHODS: Strips of human peripheral prostate (HPP), human internal prostate (HIP), and human bladder neck (HBN) were obtained from organ donors and patients with BPH. The strips were then disposed in organ baths to evaluate nitric oxide/cyclic guanosine monophosphate (cGMP)-mediated relaxation and cGMP kinetics in HPP and HIP, and electrical field stimulation (EFS)-induced neurogenic contractions in HPP and HBN. MAIN OUTCOME MEASURES: Tadalafil-induced effects on sodium nitroprusside (SNP)-induced relaxation and cGMP accumulation in HPP and HIP and influence of tadalafil and tamsulosin on EFS-induced contractions of HPP and HBN.
RESULTS: SNP-induced relaxation of HPP and HIP was significantly potentiated by tadalafil (30-60 nM). SNP-induced cGMP accumulation in HPP and HIP was enhanced by tadalafil (30-60 nM), but significant difference was only obtained in HPP. EFS-induced contractions sensitive to tetrodotoxin in HPP were significantly inhibited by tadalafil (30 nM) but not by tamsulosin (0.01-100 nM) or vehicle. Further inhibition of neurogenic responses in HPP was achieved by combining tadalafil and tamsulosin treatments. Tamsulosin, but not tadalafil, significantly reduced EFS-induced contractions in HBN, but the coadministration of both therapies resulted in additional inhibition of contractions.
CONCLUSIONS: While tadalafil enhances cGMP accumulation and potentiates prostate relaxation, tadalafil combined with tamsulosin results in enhanced inhibition of neurogenic contractions of HPP and HBN.
© 2012 International Society for Sexual Medicine.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22759598     DOI: 10.1111/j.1743-6109.2012.02821.x

Source DB:  PubMed          Journal:  J Sex Med        ISSN: 1743-6095            Impact factor:   3.802


  22 in total

Review 1.  The Impact of Medical and Surgical Treatment for Benign Prostatic Hypertrophy on Erectile Function.

Authors:  Gillian L Stearns; Jaspreet S Sandhu
Journal:  Curr Urol Rep       Date:  2015-11       Impact factor: 3.092

2.  Effects of combined treatment of tadalafil and tamsulosin on bladder dysfunction via the inhibition of afferent nerve activities in a rat model of bladder outlet obstruction.

Authors:  Akira Furuta; Yasuyuki Suzuki; Taro Igarashi; Yusuke Koike; Shin Egawa; Naoki Yoshimura
Journal:  Int Urol Nephrol       Date:  2018-03-08       Impact factor: 2.370

Review 3.  Tadalafil for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a review of clinical data in Asian men and an update on the mechanism of action.

Authors:  Osamu Yokoyama; Yasuhiko Igawa; Masayuki Takeda; Takafumi Yamaguchi; Masahiro Murakami; Lars Viktrup
Journal:  Ther Adv Urol       Date:  2015-10

Review 4.  The management of neurogenic lower urinary tract dysfunction after spinal cord injury.

Authors:  Jean-Jacques Wyndaele
Journal:  Nat Rev Urol       Date:  2016-10-25       Impact factor: 14.432

5.  Pathogenic mechanisms linking benign prostatic hyperplasia, lower urinary tract symptoms and erectile dysfunction.

Authors:  Sidney Glina; Felipe Placco Araujo Glina
Journal:  Ther Adv Urol       Date:  2013-08

6.  Ca2+ -activated K+ channel (KCa) stimulation improves relaxant capacity of PDE5 inhibitors in human penile arteries and recovers the reduced efficacy of PDE5 inhibition in diabetic erectile dysfunction.

Authors:  R González-Corrochano; Jm La Fuente; P Cuevas; A Fernández; Mx Chen; I Sáenz de Tejada; J Angulo
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

Review 7.  Phosphodiesterase-5 expression and function in the lower urinary tract: a critical review.

Authors:  Ching-Shwun Lin; Maarten Albersen; Zhongcheng Xin; Mikio Namiki; Dieter Muller; Tom F Lue
Journal:  Urology       Date:  2013-01-17       Impact factor: 2.649

8.  [New treatment strategies for male lower urinary tract symptoms].

Authors:  L F Arenas da Silva; M Schönthaler; F Cruz; C Gratzke; J Zumbe; A Stenzl; B Amend; K-D Sievert
Journal:  Urologe A       Date:  2012-12       Impact factor: 0.639

9.  Purinergic smooth muscle contractions in the human prostate: estimation of relevance and characterization of different agonists.

Authors:  Annabel Spek; Bingsheng Li; Beata Rutz; Anna Ciotkowska; Ru Huang; Yuhan Liu; Ruixiao Wang; Frank Strittmatter; Raphaela Waidelich; Christian G Stief; Martin Hennenberg
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2021-01-11       Impact factor: 3.000

10.  Concentration-dependent alpha1-Adrenoceptor Antagonism and Inhibition of Neurogenic Smooth Muscle Contraction by Mirabegron in the Human Prostate.

Authors:  Ru Huang; Yuhan Liu; Anna Ciotkowska; Alexander Tamalunas; Raphaela Waidelich; Frank Strittmatter; Christian G Stief; Martin Hennenberg
Journal:  Front Pharmacol       Date:  2021-06-24       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.